Shandong Keyuan Pharmaceutical Co Ltd
SZSE:301281
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shandong Keyuan Pharmaceutical Co Ltd
Cash & Cash Equivalents
Shandong Keyuan Pharmaceutical Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shandong Keyuan Pharmaceutical Co Ltd
SZSE:301281
|
Cash & Cash Equivalents
¥298.9m
|
CAGR 3-Years
26%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash & Cash Equivalents
¥31.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash & Cash Equivalents
¥40.9B
|
CAGR 3-Years
42%
|
CAGR 5-Years
27%
|
CAGR 10-Years
22%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash & Cash Equivalents
¥9.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
13%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Cash & Cash Equivalents
¥7.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash & Cash Equivalents
¥5.1B
|
CAGR 3-Years
73%
|
CAGR 5-Years
158%
|
CAGR 10-Years
N/A
|
|
Shandong Keyuan Pharmaceutical Co Ltd
Glance View
Shandong Keyuan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical raw materials, and chemical preparation. The company is headquartered in Jinan, Shandong. The company went IPO on 2023-04-04. The firm's main products include gliclazide, metformin hydrochloride, ropivacaine hydrochloride and others. The firm's products are used in hypoglycemic, anesthetic, cardiovascular and psychiatric diseases. The firm conducts its operations mainly in the domestic market.
See Also
What is Shandong Keyuan Pharmaceutical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
298.9m
CNY
Based on the financial report for Dec 31, 2025, Shandong Keyuan Pharmaceutical Co Ltd's Cash & Cash Equivalents amounts to 298.9m CNY.
What is Shandong Keyuan Pharmaceutical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
52%
Over the last year, the Cash & Cash Equivalents growth was 226%. The average annual Cash & Cash Equivalents growth rates for Shandong Keyuan Pharmaceutical Co Ltd have been 26% over the past three years , 52% over the past five years .
